Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Cho, B. C.; Lin, J.; Camidge, D. R.; Velcheti, V.; Solomon, B.; Lu, S.; Lee, K. H.; Kim, S. W.; Kao, S.; Diadziuskzko, R.; Beg, M.; Nagasaka, M.; Felip, E.; Besse, B.; Springfeld, C.; Popat, S.; Wolf, J.; Trone, D.; Stopatschinskaja, S.; Drilon, A. |
| Abstract Title: | Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) |
| Meeting Title: | 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 174 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Oct 26-28 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S1 |
| End Page: | S2 |
| Language: | English |
| ACCESSION: | WOS:000876973400003 |
| PROVIDER: | wos |
| DOI: | 10.1016/s0959-8049(22)00812-7 |
| Notes: | Meeting Abstract: 2LBA -- "In Plenary Session 7: Late Breaking and Proffered Papers" -- Source: Wos |
